175 related articles for article (PubMed ID: 27583701)
1. ITPA deficiency and ribavirin level are still predictive of anaemia in HCV-HIV-coinfected patients receiving ribavirin combined with a first-generation DAA (ANRS HC27 study).
Kheloufi F; Poizot-Martin I; Garraffo R; Tavenard A; Quaranta S; Renault A; Lavrut T; Bourlière M; Halfon P; Piroth L; Bellissant E; Lacarelle B; Molina JM; Solas C;
Antivir Ther; 2017; 22(6):461-469. PubMed ID: 27583701
[TBL] [Abstract][Full Text] [Related]
2. Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV-hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy.
Kheloufi F; Bellissant E; Cotte L; Poizot-Martin I; Quaranta S; Garraffo R; Barrail-Tran A; Renault A; Fournier I; Lacarelle B; Bourlière M; Molina JM; Solas C;
AIDS; 2016 Aug; 30(13):2085-90. PubMed ID: 27149089
[TBL] [Abstract][Full Text] [Related]
3. Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy.
Clark PJ; Aghemo A; Degasperi E; Galmozzi E; Urban TJ; Vock DM; Patel K; Thompson AJ; Rumi MG; D'Ambrosio R; Muir AJ; Colombo M
J Viral Hepat; 2013 Dec; 20(12):858-66. PubMed ID: 24304455
[TBL] [Abstract][Full Text] [Related]
4. Telaprevir enhances ribavirin-induced anaemia through renal function impairment.
Cotte L; Barrail-Tran A; Vincent C; Valantin MA; Fournier I; Lacombe K; Chevaliez S; Aboulker JP; Taburet AM; Molina JM;
Antivir Ther; 2015; 20(5):479-86. PubMed ID: 25560644
[TBL] [Abstract][Full Text] [Related]
5. Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin.
Kurosaki M; Tanaka Y; Tanaka K; Suzuki Y; Hoshioka Y; Tamaki N; Kato T; Yasui Y; Hosokawa T; Ueda K; Tsuchiya K; Kuzuya T; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Matsuura K; Sugauchi F; Enomoto N; Nishida N; Tokunaga K; Mizokami M; Izumi N
Antivir Ther; 2011; 16(5):685-94. PubMed ID: 21817190
[TBL] [Abstract][Full Text] [Related]
6. ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV.
Osinusi A; Naggie S; Poonia S; Trippler M; Hu Z; Funk E; Schlaak J; Fishbein D; Masur H; Polis M; Kottilil S
J Med Virol; 2012 Jul; 84(7):1106-14. PubMed ID: 22585729
[TBL] [Abstract][Full Text] [Related]
7. Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy.
Domingo P; Guardiola JM; Salazar J; Torres F; Mateo MG; Pacho C; Del Mar Gutierrez M; Lamarca K; Fontanet A; Martin J; Muñoz J; Vidal F; Baiget M
Antimicrob Agents Chemother; 2012 Jun; 56(6):2987-93. PubMed ID: 22430973
[TBL] [Abstract][Full Text] [Related]
8. Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment.
DʼAvolio A; Ciancio A; Siccardi M; Smedile A; Baietto L; Simiele M; Marucco DA; Cariti G; Calcagno A; de Requena DG; Sciandra M; Cusato J; Troshina G; Bonora S; Rizzetto M; Di Perri G
Ther Drug Monit; 2012 Apr; 34(2):165-70. PubMed ID: 22406654
[TBL] [Abstract][Full Text] [Related]
9. Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study.
Poizot-Martin I; Bellissant E; Garraffo R; Colson P; Piroth L; Solas C; Renault A; Bourlière M; Halfon P; Ghosn J; Alric L; Naqvi A; Carrieri P; Molina JM;
HIV Clin Trials; 2016 Mar; 17(2):63-71. PubMed ID: 27077673
[TBL] [Abstract][Full Text] [Related]
10. ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type.
Matsuura K; Tanaka Y; Watanabe T; Fujiwara K; Orito E; Kurosaki M; Izumi N; Sakamoto N; Enomoto N; Yatsuhashi H; Kusakabe A; Shinkai N; Nojiri S; Joh T; Mizokami M
J Viral Hepat; 2014 Jul; 21(7):466-74. PubMed ID: 24750345
[TBL] [Abstract][Full Text] [Related]
11. ITPase activity modulates the severity of anaemia in HCV-related cirrhosis treated with ribavirin-containing interferon-free regimens.
Coppola N; De Pascalis S; Messina V; Di Caprio G; Martini S; de Stefano G; Starace M; Stornaiuolo G; Stanzione M; Ascione T; Minichini C; Sangiovanni V; Zampino R; Calò F; Rinaldi L; Persico M; Federico A; Buonomo AR; Borgia G; Gaeta GB; Filippini P; Gentile I
Antivir Ther; 2017; 22(7):551-558. PubMed ID: 28165327
[TBL] [Abstract][Full Text] [Related]
12. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.
Thompson AJ; Santoro R; Piazzolla V; Clark PJ; Naggie S; Tillmann HL; Patel K; Muir AJ; Shianna KV; Mottola L; Petruzzellis D; Romano M; Sogari F; Facciorusso D; Goldstein DB; McHutchison JG; Mangia A
Hepatology; 2011 Feb; 53(2):389-95. PubMed ID: 21274861
[TBL] [Abstract][Full Text] [Related]
13. Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.
Núñez M; Ocampo A; Aguirrebengoa K; Cervantes M; Pascual A; Echeverria S; Asensi V; Barreiro P; Garcia-Samaniego J; Soriano V;
J Viral Hepat; 2008 May; 15(5):363-9. PubMed ID: 18179454
[TBL] [Abstract][Full Text] [Related]
14. ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C.
El Raziky M; Zayed NA; Abdel Baki A; Mansour SA; Shahin RMH
J Med Virol; 2017 Oct; 89(10):1823-1829. PubMed ID: 28480960
[TBL] [Abstract][Full Text] [Related]
15. Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir.
Aghemo A; Grassi E; Rumi MG; D'Ambrosio R; Galmozzi E; Degasperi E; Castaldi D; Soffredini R; Colombo M
PLoS One; 2014; 9(4):e95881. PubMed ID: 24760000
[TBL] [Abstract][Full Text] [Related]
16. Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment.
Ampuero J; Del Campo JA; Rojas L; Calleja JL; Cabezas J; Lens S; Crespo J; Forns X; Andrade RJ; Fernández I; Buti M; Millán R; Romero-Gómez M
J Clin Virol; 2015 Jul; 68():56-60. PubMed ID: 26071337
[TBL] [Abstract][Full Text] [Related]
17. Polymorphism of the inosine triphosphate pyrophosphatase gene predicts ribavirin-induced anemia in chronic hepatitis C patients.
Nishimura T; Osaki R; Shioya M; Imaeda H; Aomatsu T; Takeuchi T; Okumura Y; Fujiyama Y; Andoh A
Mol Med Rep; 2012 Feb; 5(2):517-20. PubMed ID: 22052220
[TBL] [Abstract][Full Text] [Related]
18. Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis.
Pineda-Tenor D; García-Álvarez M; Jiménez-Sousa MA; Vázquez-Morón S; Resino S
J Transl Med; 2015 Oct; 13():320. PubMed ID: 26438033
[TBL] [Abstract][Full Text] [Related]
19. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons.
Alvarez D; Dieterich DT; Brau N; Moorehead L; Ball L; Sulkowski MS
J Viral Hepat; 2006 Oct; 13(10):683-9. PubMed ID: 16970600
[TBL] [Abstract][Full Text] [Related]
20. Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients.
D'Avolio A; De Nicolò A; Cusato J; Ciancio A; Boglione L; Strona S; Cariti G; Troshina G; Caviglia GP; Smedile A; Rizzetto M; Di Perri G
Antiviral Res; 2013 Oct; 100(1):114-9. PubMed ID: 23933495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
